BASE and HER2 for use as tumor markers for breast cancer

BASE 和 HER2 用作乳腺癌肿瘤标志物

• 批准号: 7079089
• 负责人: Kristi Egland
• 金额: $ 13.01万
• 依托单位: UNIVERSITY OF SOUTH DAKOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7079089
• 关键词: Native Americans; breast neoplasms; female; gene expression; genetic markers; genetic susceptibility; health disparity; human population genetics; human subject; natural gene amplification; neoplasm /cancer epidemiology; neoplasm /cancer genetics; patient oriented research; protooncogene; women' s health

The overall goals of the research project administered through the South Dakota Health Research Foundation are to define the frequency of breast cancers from American Indian patients that express a novel tumor marker designated BASE and to investigate overexpression of HER2 in breast cancers isolated from American Indian females. This information will determine whether BASE and HER2 are useful breast cancer tumor markers in American Indians. This research will explore the presence of a newly discovered tumor marker, BASE, and amplification of a clinically validated marker, HER2, in breast cancers from Native American women. The knowledge gained from this proposal will advance our understanding of whether BASE could be used as a tumor marker for breast cancer in American Indian women. In addition, we will begin to determine the status of HER2 overexpression in breast cancers from American Indians. In order to accomplish these goals, I propose the following specific aims: Specific Aim 1. Determine frequency and types of breast cancers from American Indian women that express BASE. Specific Aim 2. Investigate the status of HER2 amplification in breast cancers from American Indian women. One long-term goal of this research program is to validate whether the Esr1, Pgr, BRCA1, BRCA2 and the extent of HER2 amplifications accurately predict treatment and overall survival of American Indian females with breast cancer. This pilot project will give us the opportunity to begin to investigate the status of HER2 amplification in American Indian breast cancers. In the future, it will also be necessary to analyze the status of the Esr1 and Pgr in the same samples.

通过南达科他州卫生研究基金会管理的研究项目的总体目标是定义来自美洲印第安人患者的乳腺癌的频率，这些乳腺癌表达了一种新型的肿瘤标记，并调查了与美国印度女性分离的乳腺癌中HER2的过表达。这些信息将确定基础和HER2是否是美洲印第安人的有用的乳腺癌肿瘤标记。这项研究将探索新发现的肿瘤标记物，基础，并在美国原住民妇女的乳腺癌中的临床验证标记HER2放大。从这项提案中获得的知识将提高我们对是否是否 在美洲印第安妇女中，碱可以用作乳腺癌的肿瘤标记。此外，我们将开始确定美国印第安人乳腺癌中HER2过表达的状态。为了实现这些目标，我提出了以下特定目的：特定目的1。确定表达基础的美国印度妇女的乳腺癌的频率和类型。 具体目的2。研究美洲印第安妇女的乳腺癌中HER2扩增的状况。该研究计划的一个长期目标是验证ESR1，PGR，BRCA1，BRCA2以及HER2扩增的程度是否可以准确预测美洲印度女性患有乳腺癌的治疗和总体生存。该试点项目将使我们有机会开始研究美洲印第安乳腺癌中HER2扩增的状况。将来，还必须在同一样本中分析ESR1和PGR的状态。